Literature DB >> 17713435

Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model.

Toshie Okada1, Tokihiko Sawada, Keiichi Kubota.   

Abstract

BACKGROUND: The renoprotective effect of erythropoietin (EPO) and the nonhematopoietic EPO, asialoEPO was investigated in a murine ischemia-reperfusion injury (I/R) model.
METHODS: I/R was created by clamping the right renal pedicle for 60 min after left nephrectomy. Balb/c mice were divided into four groups (n=15 in each group): sham operation (Sham), vehicle treatment (Vehicle), EPO treatment (EPO), and asialoEPO treatment (AsialoEPO). EPO and asialoEPO were given at a dose of 500 IU/kg 30 min before I/R. Plasma creatinine (Cr), survival, and the number of apoptotic cells were analyzed. Protein expression was analyzed by Western blotting.
RESULTS: Plasma Cr level was not significantly different at 6 hr after I/R. At 24 hr after I/R, the Cr (mg/dL) levels in Sham, Vehicle, EPO, and asialoEPO were 0.13+/-0.01, 1.24+/-0.70, 0.24+/-0.08, and 0.25+/-0.13, respectively (P<0.05). The numbers of apoptotic cells in these groups were 0.1+/-0.1, 98.9+/-42.6, 3.3+/-0.7, and 2.9+/-1.6, respectively (P<0.05). Western blotting revealed that in kidney tissue of mice treated with EPO and asialoEPO, p38-MAPK and the proapoptotic molecule Bad was decreased, and the antiapoptotic molecules Bcl-xL and XIAP were increased. Survival rates at 7 days after I/R injury in the Sham, Vehicle, EPO, and AsialoEPO groups were 100%, 21.4%, 23.1%, and 53.8%, respectively (P=0.05).
CONCLUSION: EPO and asialoEPO attenuated renal dysfunction caused by I/R in mouse kidney at the same level, but only asialoEPO improved survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17713435     DOI: 10.1097/01.tp.0000277672.02783.33

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

Review 1.  The receptor that tames the innate immune response.

Authors:  Michael Brines; Anthony Cerami
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  HCaRG accelerates tubular repair after ischemic kidney injury.

Authors:  Hiroyuki Matsuda; Julie L Lavoie; Louis Gaboury; Pavel Hamet; Johanne Tremblay
Journal:  J Am Soc Nephrol       Date:  2011-09-15       Impact factor: 10.121

3.  Two-step purification procedure for recombinant human asialoerythropoietin expressed in transgenic plants.

Authors:  Farooqahmed S Kittur; Elena Arthur; Maikhanh Nguyen; Chiu-Yueh Hung; David C Sane; Jiahua Xie
Journal:  Int J Biol Macromol       Date:  2014-10-25       Impact factor: 6.953

4.  Erythropoietin ameliorates early ischemia-reperfusion injury following the Pringle maneuver.

Authors:  Masato Kato; Tokihiko Sawada; Junji Kita; Mitsugi Shimoda; Keiichi Kubota
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

5.  C-Terminally fused affinity Strep-tag II is removed by proteolysis from recombinant human erythropoietin expressed in transgenic tobacco plants.

Authors:  Farooqahmed S Kittur; Mallikarjun Lalgondar; Chiu-Yueh Hung; David C Sane; Jiahua Xie
Journal:  Plant Cell Rep       Date:  2014-12-14       Impact factor: 4.570

6.  A Novel Plant-Produced Asialo-rhuEPO Protects Brain from Ischemic Damage Without Erythropoietic Action.

Authors:  Maotao He; Farooqahmed S Kittur; Chiu-Yueh Hung; Jianhui Zhang; Li Jing; David C Sane; P Andy Li; Jiahua Xie
Journal:  Transl Stroke Res       Date:  2021-09-22       Impact factor: 6.829

7.  Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model?

Authors:  A Sonoda; N Nitta; A Seko; S Ohta; S Takemura; T Sugimoto; T Uzu; Y Yokomaku; M Takahashi; A Kashiwagi; K Murata
Journal:  Br J Radiol       Date:  2009-06-22       Impact factor: 3.039

8.  Cytoprotective effect of recombinant human erythropoietin produced in transgenic tobacco plants.

Authors:  Farooqahmed S Kittur; Mamudou Bah; Stephanie Archer-Hartmann; Chiu-Yueh Hung; Parastoo Azadi; Mayumi Ishihara; David C Sane; Jiahua Xie
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

Review 9.  Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care.

Authors:  Nimesh S A Patel; Kiran K Nandra; Christoph Thiemermann
Journal:  Crit Care       Date:  2012-07-26       Impact factor: 9.097

Review 10.  Erythropoietin Receptor/β Common Receptor: A Shining Light on Acute Kidney Injury Induced by Ischemia-Reperfusion.

Authors:  Yuanyuan Wu; Bin Yang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.